Everything below concerns GLP-1 receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
After college, Guillaume joined the Karamu Players in Cleveland and performed in musical comedies and opera. He toured the world in 1959 as a cast member of the Broadway musical Free and Easy. He made his Broadway debut in Kwamina in 1961. His other stage appearances included Golden Boy (with Sammy Davis Jr.), Tambourines to Glory, Guys and Dolls, for which he received a Tony Award nomination, Jacques Brel is Alive and Well and Living in Paris, and Purlie. His additional roles included Katherine Dunham's Bambouche and in Fly The Blackbird. In 1964, Guillaume portrayed Sportin' Life in a revival of Porgy and Bess at New York City Center. Guillaume was a member of the Robert De Cormier Singers, performing in concerts and on television. He recorded an LP album, Columbia CS9033, titled Just Arrived, as a member of The Pilgrims, a folk trio, with Angeline Butler and Millard Williams. Columbia records producer Tom Wilson had set out to create the Pilgrims as an answer to the popular folk trio Peter, Paul and Mary. By early 1964, the Pilgrims had recorded a handful of songs and Wilson was looking for the right song for the group's debut single when a then-unknown singer/songwriter named Paul Simon arrived for a meeting with Wilson and eventually pitched his new composition, "The Sound of Silence". Wilson liked the song and had Simon record a demo for the group, but when Simon and his friend, Art Garfunkel, sang the song for Wilson in person, he signed them to a record contract instead of using it for The Pilgrims.
Promising results of therapeutic candidates are reported: phase I trialed ultrasound BBB-opening device against brain cancer (1 May), phase I trialed personalized mRNA vaccine against pancreatic cancer recurrence (10 May), a novel antibiotic (Streptothricin F) against ABR bacteria (9 May), an e-skin for prosthetic sensing (18 May), two-dose JYNNEOS vaccine against mpox appears ~86% (19 May) or ~66% (18 May) effective, and a xenografted mice-tested pan-KRAS-inhibitor against cancer (31 May).
== Industry == In 2020, the American market for dietary supplements was valued at $140.3 billion, with the economic impact in the United States for 2016 estimated at $122 billion, including employment wages and taxes. A 2020 analysis projected that the global market for vitamins and dietary supplement products would reach $196.6 billion by 2028, where the growth in market size is largely attributed to recent technological advancements in product manufacturing, increased demand for products advertised as healthy, increased product availability, and population aging.
== Organisation == The Police Manual of West Bengal Police was compiled and issued during British Raj and is known as the Police Regulations of Bengal (PRB), 1943 and with subsequent modifications and corrections, is the guiding source of internal Police Organization and Administration under its area of responsibility. The WBP is divided into a number of units:
== Legacy == A weapon similar to the Gravity Gun, known as the Grabber, was introduced in the 2005 Doom 3 expansion pack, Resurrection of Evil. Dead Space (2008) was planned to incorporate a device called the TK Gun to pick up and throw objects, which became the Kinesis Module. Rage 2 (2018) featured a purely combat-oriented gravity gun that allowed players to slam enemies against walls when tagged with special bullets. The Gravity Gun is one of several video game weapons used in a climactic fight for the 2021 film Free Guy. The handheld multitool in Squadron 42 was compared to a Gravity Gun by critics. Valve's 2020 virtual reality game Half-Life: Alyx, a prequel to Half-Life 2, contains a pair of "gravity gloves" wielded by protagonist Alyx Vance, which provide function similar to the gravity gun with the ability to lift and throw objects, though tailored to work as standard VR in-game hand controls. The Portal Gun, formally the Aperture Science Handheld Portal Device, featured in the Portal series was also inspired by the Gravity Gun, featuring a similar three-pronged science fiction design. Both the Gravity Gun and Portal Gun, while superficially resembling directed-energy weapons, instead function moreso as tools to reward lateral thinking and manipulating one's environment to overcome obstacles. The Portal Gun introduced in Portal 1 (2007) refines such gameplay concepts to focus entirely on transportation and puzzle-solving, allowing the player to avoid and outmaneuver hazards rather than facing them head on.
Sources: en.wikipedia.org
As with most medical evaluation and diagnosis, history and physical examination are vital to making an accurate diagnosis. Radiographic evaluation is the gold standard to diagnosing a fracture and creating a treatment plan. If there is concern for fracture extension into the joint that is not adequately visualized on radiographs, a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) should be considered. MRI is especially useful to classify or grade degree of condral damage. Advanced imaging, CT or MRI is a common modality for surgical planning.
=== As the OAM (1991–1998) === Joseph J. Jacobs was appointed the first director of the OAM in 1992. Jacobs' support for rigorous scientific methodology caused friction with Democrat U.S. Senator Tom Harkin and other OAM patrons. Harkin believed his allergies had been cured by bee pollen pills and expressed frustration with the "unbendable rules" of randomized clinical trials, saying, "it is not necessary for the scientific community to understand the process before the American public can benefit from these therapies." Harkin's office reportedly pressured the OAM to fund studies of favored theories, including the use of bee pollen and antineoplastons as treatments. OAM board member Barrie Cassileth publicly criticized the office as a purveyor of nonsense and described it as a "place where opinions are counted as equal to data". After Harkin appeared on television in 1994 with cancer patients who blamed Jacobs for blocking their access to antineoplastons, Jacobs resigned from the OAM in frustration. In an interview with Science, Jacobs criticized Harkin and other politicians for pressuring his office, promoting certain therapies, and, he says, attempting an end-run around objective science." Harkin drew support from Iowa Democrat Representative Berkley Bedell, who believed that cow colostrum had cured his Lyme disease. The OAM's budget grew in the 1990s. The office drew increasing criticism for its perceived lack of rigorous scientific study of alternative approaches favoring uncritical boosterism.
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis, under development by Anthos Therapeutics. It is anti-factor XI antibody. The hope behind its development is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding. It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke. Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban. Antibody Monoclonal antibody Immunology
Chiedozie Ngozi Egesi is a Nigerian plant scientist and professor. He is director of numerous research projects dedicated to international agriculture, gender equity and food and nutrition security in agriculture. He received the Achiever in Agriculture Award in 2021 by the Nigeria Agriculture Awards in 2021 and the Kwame Nkrumah Leadership Prize in 2022. Egesi grew up in a farming community in Umuahia South, Abia State. He received a Bachelor of Science from the University of Calabar in 1994 and a Master in Science on Environmental Biology at University of Ibadan in 1997. He earned a Ph.D in Agricultural Biology from University of Ibadan in 2001 He took certificate courses on Statistical Genetics at the University of Washington, Seattle, USA in 2007 and Spring class on Qualitative Trait Loci Analyses and Statistical Genetics at the Cornell University Ithaca, New York in April, 2012.
Yeast estrogen screen (YES) and Yeast androgen screen (YAS) are in vitro screens that have been developed in order to detect estrogenic and androgenic activities, respectively, of natural and synthetic compounds, mixtures and environmental samples. The test is based on genetically modified yeast cells (Saccharomyces cerevisiae), which contain the gene for the human estrogen or androgen receptor coupled to a reporter gene (e.g. lacZ). Activation of the receptor initiates a cascade of events leading to the expression of the reporter gene product (e.g. β-galactosidase) which converts a substrate (e.g. CPRG) which leads to a measurable color change from yellow to red in the medium. Alternative systems are based on the generation of a luminescence signal. Activating (agonistic) samples can be measured directly; inhibiting (antagonistic) activities are measured as the reduction of color development in the presence of a known activating substance.
Sources: en.wikipedia.org
== Toxicity == Though few people come in contact with fermium, the International Commission on Radiological Protection has set annual exposure limits for the two most stable isotopes. For fermium-253, the ingestion limit was set at 107 becquerels (1 Bq equals one decay per second), and the inhalation limit at 105 Bq; for fermium-257, at 105 Bq and 4,000 Bq respectively.
Greater lactose tolerance has come about in two ways. Some populations have developed genetic changes to allow the digestion of lactose: lactase persistence. Other populations developed cooking methods like milk fermentation. Lactase persistence in humans evolved relatively recently (in the last 10,000 years) among some populations. Around 8,000 years ago in modern-day Turkey, humans became reliant on newly-domesticated animals that could be milked; such as cows, sheep, and goats. This resulted in higher frequency of lactase persistence. Lactase persistence became high in regions such as Europe, Scandinavia, the Middle East and Northwestern India. However, most people worldwide remain lactase non-persistent. Populations that raised animals not used for milk tend to have 90–100 percent of a lactose intolerant rate. For this reason, lactase persistence is of some interest to the fields of anthropology, human genetics, and archaeology, which typically use the genetically derived persistence/non-persistence terminology. The rise of dairy and producing dairy related products from cow milk alone, varies across different regions of the world, aside from genetic predisposition. The process of turning milk into cheese dates back earlier than 5200 BC. DNA analysis in February 2012 revealed that Ötzi was lactose intolerant, supporting the theory that lactose intolerance was still common at that time, despite the increasing spread of agriculture and dairying.
Located close to the city centre, the university campus stretches along the River Corrib. The oldest part of the university, the Quadrangle with its Aula Maxima, was designed by John Benjamin Keane in a Tudor Gothic architectural style and was constructed from local limestone; it is a replica of Christ Church, one of the colleges at the University of Oxford. The Queen's University was dissolved on 3 February 1882 under the University Education (Ireland) Act 1879, and was replaced by the Royal University of Ireland (RUI), which had been established on 27 April 1880. Under the Irish Universities Act 1908, the RUI was dissolved and was replaced by the National University of Ireland (NUI) and Queen's University of Belfast (QUB). The name of Queen's College, Galway, was changed to University College, Galway (UCG), and it became a constituent college of the new National University of Ireland, together with University College Dublin (UCD), and University College Cork (UCC). Queen's College, Belfast, became an independent university, called the Queen's University of Belfast. University College, Galway (UCG), was given special statutory responsibility under the University College Galway Act 1929 with respect of the use of the Irish language as a working language of the university. Members of the Franciscan Order from St. Anthony's College would have studied for degrees in UCG, similarly members of the Society of African Missions at their House of Philosophy, at Cloughballymore, Kilcolgan, Co Galway, studied for degrees in UCG. St. Anthony's is now used by the J.E.
=== For acute coronary syndrome === The combination of a P2Y12 inhibitor and aspirin, called dual antiplatelet treatment, remains the first-line treatment for acute coronary syndrome. A 2019 randomized trial suggested that prasugrel is superior to ticagrelor.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.